MILAN — December 20, 2022 — AAVantgarde Bio (AAVantgarde) , a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders, is pleased to congratulate Professor Alberto Auricchio, the Company’s Founder and Chief Scientific Officer (CSO), on his election as Vice President and Board member of the European Society of Gene and Cell Therapy (ESGCT). The ESGCT Board is composed of researchers and clinicians representing a broad range of European Countries. Members are elected by nomination and vote at the Annual General Meeting. Election to the Board of ESGCT is a great honor and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
As well as being CSO of AAVantgarde,Professor Auricchio is Coordinator of the Molecular Therapy Program at TIGEM and Professor of Medical Genetics at University “Federico II” in Naples, Italy. He is co-author of over 140 peer-reviewed publications and inventor of several patents related to the use of viral vectors for gene therapy and has received the Outstanding New Investigator Award of the American Society of Gene Therapy and the International Prize for Scientific Research “Arrigo Recordati.”
Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde said, “Many congratulations to Alberto on this important and well-deserved recognition of his outstanding scientific contributions to the field of Adeno-Associated Viral Vectors (AAV) gene therapies. We are honoured to work with him as Founder and Chief Scientific Officer of our company.
About AAVantgarde Bio
AAVantgarde Bio (http://www.aavantgardebio.com/), a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and supported by Sofinnova Partners. AAVantgarde’s platforms are focused on broadening the application of AAV based therapies by addressing the limitations of single AAV therapies cargo capacity. Approximately 1,200 ocular and non-ocular human coding sequences are above standard AAV carrying capacity and could be leveraged using our platform technology.
For more information visit: www.aavantgardebio.com
Julia Wilson - JW Communications
Phone: +44 (0) 7818 430877
Elicit Plant makes C&EN’s list of '10 Start-Ups to Watch'
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
Myricx Bio appoints Dr Chris Martin, biotech entrepreneur and ADC pioneer, as Chairman of its Board of Directors
AAVantgarde appoints Dr. Peter K. Kaiser to the Board of Directors
Recor Medical and Otsuka Medical Devices announce first FDA-approved Renal Denervation System for the treatment of hypertension